The CCM2 (cerebral cavernous malformation 2) antibody is a key tool for studying the CCM2 protein, which plays a critical role in vascular development and homeostasis. CCM2. encoded by the CCM2 gene (also known as OSM or MGC4607), forms a ternary complex with KRIT1 (CCM1) and PDCD10 (CCM3) to regulate endothelial cell signaling, angiogenesis, and vascular integrity. This complex primarily modulates the MEKK3–KLF2/4 signaling pathway, influencing cell adhesion, apoptosis, and endothelial barrier function. Mutations in CCM2 are linked to cerebral cavernous malformations (CCMs), vascular lesions in the central nervous system that predispose individuals to seizures, hemorrhages, and neurological deficits.
CCM2 antibodies are widely used in research to detect protein expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate CCM2's interaction networks, subcellular localization, and dysregulation in disease models. Additionally, these antibodies aid in investigating molecular mechanisms underlying CCM pathogenesis, such as disrupted Rho GTPase signaling or hyperpermeable vasculature. Commercial CCM2 antibodies are typically validated for specificity in human, mouse, or rat tissues, supporting translational studies aiming to develop targeted therapies for CCMs. Their application extends to screening genetic mutations and evaluating therapeutic interventions in preclinical studies.